HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung
Cellular plasticity is a hallmark of cancer, enabling tumor cells to alter identity and evade therapeutic pressure. In invasive mucinous adenocarcinoma of the lung (IMA), NK2 homeobox 1 (NKX2-1) loss triggers a pulmonary to gastric switch marked by aberrant activation of hepatocyte nuclear factor 4 alpha (HNF4α), a master regulator of gastrointestinal/hepatic differentiation. We show that HNF4α promotes IMA growth and activates a gastric pit cell-like program. Loss of HNF4α enables forkhead box A1/A2 (FoxA1/2) transcription factors to bind de novo sites and activate alternative, non-gastric identities in IMA. HNF4α also establishes a mucinous program associated with tolerance to KRAS blockade, and loss of HNF4α enhances response to KRASG12D inhibition. Mechanistically, HNF4α blocks cell cycle exit in drug-tolerant persister cells and promotes activity of the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). NRF2 activation partially rescues effects of Hnf4a deletion on KRASG12D inhibition, whereas NRF2 inhibition enhances sensitivity to KRASG12D blockade. Thus, HNF4α is a key regulator of growth, identity, and primary response to KRASG12D inhibition in IMA.
Authors
- Minzhe Guo (ORCID: https://orcid.org/0000-0002-5502-9172)
- Yangsook Song Green (ORCID: https://orcid.org/0000-0003-3620-0971)
- Eric L. Snyder (ORCID: https://orcid.org/0000-0003-3591-3195)
- Matthew Gumbleton (ORCID: https://orcid.org/0000-0003-4882-4116)
- Henry U. Arnold
- Benjamin T. Spike (ORCID: https://orcid.org/0000-0002-0893-3302)
- Yutaka Maeda (ORCID: https://orcid.org/0000-0002-9537-3971)
- Headtlove Essel Dadzie (ORCID: https://orcid.org/0000-0002-2108-7956)
- Soledad Camolotto
- Mari Mino-Kenudson
Institutions
- Harvard University (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Massachusetts General Hospital (US)
- Perinatal Institute (GB)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1172/jci198282
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00